Main content

    Leukemia

    Adult Clinical Trials Main Page

    CPMC Cancer Services

    Further protocol information can be found on the links below at ClinicalTrials.gov

    Principal Investigator/Contact Information Protocol Title Patient Population Recruitment Period
    Principal Investigator:
    CPMC Oncologists

    Contact:
    Brenda Eng
    415-600-1775    		 Cytogenetic Studies in Leukemia Patients (Ancillary Cytogenetic Study (registry) SWOG 9007. Subjects with Leukemia Open
    Principal Investigator:
    CPMC Oncologists

    Contact:
    Brenda Eng
    415-600-1775    		 Leukemia Centralized Reference Laboratory and Tissue Repository (registry) SWOG 9910. Subjects with Leukemia or Myelodysplasia Open
    Principal Investigator:
    CPMC Oncologists

    Contact:
    Brenda Eng
    415-600-1775    		 A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) Induction Therapy vs. Standard Induction with Daunomycin and cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 61 with Previously Untreated DeNovo Acute Myeloid Leukemia (AML). SWOG S0106.Subjects under age 61 with previously untreated DeNovo Acute Myeloid LeukemiaClosed to Enrollment



    updated: 9/2010

    Back to top